Who is sponsoring NCT04678518?

NCT04678518 is sponsored by Hamad Medical Corporation.

What drugs are being tested in NCT04678518?

Interventions in NCT04678518: Inflammatory makers that will include Interleukins (IL); IL1, IL2, IL6 and TNF.

Is NCT04678518 still recruiting?

NCT04678518 is currently status unknown. Last updated 19 May 2022.

Last reviewed 2022-05-19 · How we verify

NCT04678518: ECMO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Inflammatory Markers Dynamics in Response to Extra-corporeal Membrane Oxygenator Decannulation

Status unknown NA Last updated 19 May 2022

What this trial tests

NA trial testing Inflammatory makers that will include Interleukins (IL); IL1, IL2, IL6 and TNF in Inflammatory Markers Changes in Response to Extra-corporeal Membrane Oxygenator Decannulation in 30 participants. Status unknown.

Timeline

28 February 2023

Primary endpoint
31 October 2023

31 December 2023

Quick facts

Lead sponsor	Hamad Medical Corporation
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	single
Primary purpose	screening
Enrollment	30
Start date	28 February 2023
Primary completion	31 October 2023
Estimated completion	31 December 2023
Sites	2 locations across Qatar

Drugs / interventions tested

Inflammatory makers that will include Interleukins (IL); IL1, IL2, IL6 and TNF

Conditions studied

Inflammatory Markers Changes in Response to Extra-corporeal Membrane Oxygenator Decannulation — all drugs for Inflammatory Markers Changes in Response to Extra-corporeal Membrane Oxygenator Decannulation →

Sponsor

Hamad Medical Corporation — full company profile →

Who can join

Adults 18 to 70, any sex, with Inflammatory Markers Changes in Response to Extra-corporeal Membrane Oxygenator Decannulation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Extracorporeal membrane oxygenation (ECMO) aim at providing cardiac, respiratory support, or both. The use of ECMO could be associated with systemic inflammatory response syndrome (SIRS) at the time of initiation or the time of decannulation. There is an existing evidence to state that clinical criteria of SIRS accompany decannulation. We aim at proving this relation through studying the inflammatory markers changes before and after decannulation. The investigators will study all participants who require ECMO support in the heart hospital, all patient will be subjected to clinical evaluation of the SIRS criteria plus studying the inflammatory makers that will include IL1, IL2, IL6 and TNF before and after decannulation. Participants will be divided based on the SIRS criteria into 2 groups and both groups will be compared using Chi-Square analysis (Fisher tests if small sample size) or two tailed t-test, as appropriate

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Pro-inflammatory cytokines in response to systemic inflammatory response syndrome post extra-corporeal membrane oxygenator decannulation.
Bilal O, Omar AS, Tbishat L, Salama A, et al · · 2026 · PMID 41383076 · DOI 10.1177/03913988251398846

Verify or expand the search:

Other Hamad Medical Corporation trials

Trials by the same sponsor.

NCT07333209 — Scheduled Positioning With a Peanutball(SPP) on Labor Outcomes Among Primiparous Women Under Epidural Analgesia · NA · recruiting
NCT07270939 — Optimizing Enteral Nutrition Regimen for Critically Ill Patients · NA · not yet recruiting
NCT07307508 — Efficacy of Scalp Block in Managing Post Subarachnoid Hemorrhage Headache in Critically Ill Patients. A Single Centre Ra · NA · recruiting
NCT06622577 — The Effect of Dietary Management and Cysteine Supplementation on Growth Parameters and Biochemical Control for Pediatric · NA · not yet recruiting
NCT06887855 — Enhancing Post-Stroke Dysphagia Rehabilitation · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04678518 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hamad Medical Corporation
Last refreshed: 19 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04678518.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing